Syapse, creators of the Precision Medicine Data Platform, today announced that it raised
The amount of information a physician must synthesize in making a diagnosis and treatment decision is increasing exponentially. Critical data is locked up in electronic medical records, and new data-producing technologies such as genetic sequencing are being deployed at point of care.
The Syapse Precision Medicine Data Platform integrates complex genomic and clinical data with care pathways and medical knowledge bases, providing clinicians with actionable insights to enable diagnosis and treatment. The Syapse platform enables longitudinal tracking of patients over time, creating expansive sources of real world evidence that will be used to power learning health systems across networks of affiliated health providers. The platform integrates data from electronic medical records, molecular testing labs, imaging and billing systems, and is agnostic to the data source or system.
Today, Syapse software is being used to transform the care of complex diseases, such as cancer. In close collaboration with both academic and community healthcare providers, Syapse helps accelerate the deployment of precision medicine programs. One recently announced collaboration with
"At Syapse, we are focused on improving healthcare though software that helps clinicians utilize complex genomic and clinical data," said
"Healthcare is at the precipice of a complete transformation that places patients at the center of the healthcare ecosystem and elevates quality and outcomes over quantity and volume," said
Syapse is a software company enabling healthcare providers to deploy precision medicine programs. Leading academic and community healthcare providers use the Syapse Precision Medicine Data Platform to integrate complex genomic and clinical data to provide clinicians with actionable insights at point of care, enabling diagnosis, treatment, and outcomes tracking. Headquartered in
About The Social+Capital Partnership
The Social+Capital Partnership ("
Except for the historical information and discussions contained herein, statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements are subject to risks and uncertainties. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the deployment of capital, the fact that our partner companies may vary from period to period, our substantial capital requirements and absence of liquidity from our partner company holdings, fluctuations in the market prices of our publicly traded partner company holdings, competition, our inability to obtain maximum value for our partner company holdings, our ability to attract and retain qualified employees, market valuations in sectors in which our partner companies operate, our inability to control our partner companies, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our partner companies, including the fact that most of our partner companies have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which Safeguard's partner companies operate, and other uncertainties described in our filings with the
Read the full story at http://www.prweb.com/releases/2014/07/prweb12000142.htm
Most Popular Stories
- Prosecutor to Investigate Walmart Police Shooting
- GM to Announce New Jobs in Tennessee
- Michael Brown Funeral: Can Americans Change the Script of Violence?
- Emirates Hit Libyan Targets With Airstrikes
- Smith & Wesson Misses Target
- American Killed With ISIS Fighters in Syria
- Marco Rubio Warns Obama on Deportations
- Ford Hires 300 at Louisville Lincoln Plant
- Surf's Up! SoCal Prepares for Big Storm Surf
- Hamas Claims Gaza Ceasefire as Victory Over Israel